Table 5 Survival

From: Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

 

ACE

PE

All Patients

  

 Median survival (months)

9.7

10.6

 1-year survival (%)

34

38

 2-year survival (%)

12

12

LD

  

 Median survival (months)

10.9

12.6

 1-year survival (%)

44

54

 2-year survival (%)

19

16

ED

  

 Median survival (months)

8.3

7.5

 1-year survival (%)

17

15

 2-year survival (%)

0

3

Back to article page